title: [Factors associated with medical management of HIV infected persons in two French districts, 1993-1995].
abstract: BACKGROUND
  The regularity of medical followup of HIVinfected patients greatly influences the effectiveness of antiretroviral treatments and of prophylaxis of opportunistic infections.
  
  
  METHODS
  To identify potential barriers to a regular followup, a retrospective study was conducted among the adult AIDS patients diagnosed between July 1993 and May 1995 in two French districts (Gironde and HautsdeSeine). Medical followup was described based on the frequency of CD4 counts in the medical file and on a confidential interview among patients whose HIV infection had been diagnosed at least 6 months before AIDS. Irregular followup (less than one CD4 count per year when CD4> 500/ mm(3), and per 6months when CD4< 500/ mm(3)) within the two years preceding AIDS diagnosis was analysed according to socioeconomic status and to social and behavioral factors.
  
  
  RESULTS
  Among 290 patients, followup was irregular in 51% of the patients (injecting drug users: 66%, homo/bisexual men: 41%, patients infected through heterosexual contact: 49%, p<0.01). Factors independently associated with irregular followup were low income level (adjusted odds ratio (aOR)= 2.4; 95% confidence interval (CI), 1.44.1); absence of regular practitioner at HIV diagnosis (aOR= 1.9; 95% CI 1.13.3); imprisonment between HIV diagnosis and AIDS (aOR= 3.8; 95% CI 1.310. 9), and being non homo/bisexual male (aOR= 2.4; 95% CI 1.15.1) versus homo/bisexual male (aOR= 1.3; 95% CI 0.72.7) and female (reference).
  
  
  CONCLUSIONS
  Results of this study show that several socioeconomic, psychological and cultural barriers to a regular preAIDS medical followup still exist. Impact of new antiretroviral therapy may only be optimal if these barriers are overcome.
authors.affiliation: Centre Européen pour la Surveillance Epidémiologique du Sida, Hôpital National de SaintMaurice, 14 rue du Val d'Osne, 94410 SaintMaurice, France.
authors.forename: V
authors.initials: V
authors.lastname: Schwoebel
authors.forename: M S
authors.initials: MS
authors.lastname: Delmas
authors.forename: C
authors.initials: C
authors.lastname: Michon
authors.forename: J S
authors.initials: JS
authors.lastname: Hubert
authors.forename: E
authors.initials: E
authors.lastname: Couturier
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: F
authors.initials: F
authors.lastname: Boué
authors.forename: A S
authors.initials: AS
authors.lastname: Simonpoli
authors.forename: F
authors.initials: F
authors.lastname: Dabis
authors.forename: J B
authors.initials: JB
authors.lastname: Brunet
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D006296:Health Services / Q000706:statistics & numerical data; D006801:Humans; D016015:Logistic Models; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D012959:Socioeconomic Factors; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents